文献速递主动脉疾病

既往腹主动脉瘤腔内修复术后破裂:围术期死亡率影响因素的系统评价与Meta回归分析

Rupture after previous endovascular abdominal aortic aneurysm repair: A meta-analysis and meta-regression analysis of factors influencing perioperative mortality.
PubMed 文献 · J Vasc Surg · 2025-03-20

该系统评价与Meta分析纳入30项研究(743例患者,746次破裂),评估既往EVAR术后晚期破裂的临床表现、处理与结局。汇总围术期死亡率为29.5%(95%CI 23.8-35.8),腔内治疗亚组显著低于开放修复(风险比0.62,95%CI 0.44-0.86)。Meta回归显示围术期死亡率近年似有下降,开放修复中完全取出内移植物时死亡率显著更高。

要点

  • 既往EVAR术后晚期破裂的平均破裂时间为48个月(范围16-81个月),随访依从性均值68%(95%CI 58-77)。
  • I型与III型内漏是破裂的主要原因(88%),37%(95%CI 28-47)的患者血流动力学不稳定。
  • 汇总围术期死亡率为29.5%(95%CI 23.8-35.8),腔内治疗亚组显著低于开放修复(风险比0.62,95%CI 0.44-0.86)。

核心结论

  • 既往EVAR术后晚期破裂是灾难性事件,死亡风险相当高。
  • EVAR与显著更低的围术期死亡率相关,只要可行应优先选择。
  • 需要开放修复时,完全取出内移植物与更高的死亡率相关,因此应鼓励保留内移植物的功能部分。

研究设计与样本

  • 系统评价与Meta分析,遵循PRISMA指南,检索至2024年2月。
  • 纳入报告既往EVAR术后晚期破裂(>30天)行EVAR或开放修复的研究。
  • 共纳入30项研究,743例患者,746次破裂。
  • 主要终点为围术期(院内或30天)死亡率,采用随机效应Meta分析及Meta回归。

主要发现

  • EVAR术后平均5年随访期间破裂的累积发生率为1.5%。
  • 从初次EVAR到破裂的平均时间为48个月(范围16-81个月)。
  • 随访依从性均值为68%(95%CI 58-77),32%(95%CI 24-40)的病例至少有过一次既往动脉瘤相关再干预。
  • I型和III型内漏是破裂的主要原因(88%),37%(95%CI 28-47)的患者血流动力学不稳定。
  • 接受手术的患者中,247例(38%)经腔内处理,409例(62%)行开放修复;汇总围术期死亡率为29.5%(30项研究;95%CI 23.8-35.8),腔内亚组显著更低(20项研究;风险比0.62;95%CI 0.44-0.86)。

关键数值与推荐

  • Meta回归显示围术期死亡率近年似有下降(-0.0545;P=0.04)。
  • 腔内亚组中,较大样本系列围术期死亡率下降(-0.0375;P=0.01)。
  • 开放修复亚组中,需要完全取出内移植物时围术期死亡率显著更高(0.0121;P=0.03)。

临床怎么用

  • 作者认为,EVAR与显著更低的围术期死亡率相关,只要可行应优先选择。
  • 作者认为,需要开放修复时,完全取出内移植物携带更高死亡率,因此应鼓励保留内移植物的功能部分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To document the clinical presentation, management, and outcome of patients presenting with late rupture of abdominal aortic aneurysm after previous endovascular aneurysm repair (EVAR) and to investigate which factors may influence the perioperative mortality. METHODS: A systematic review and meta-analysis of relevant studies was undertaken to February 2024 in conformity with the PRISMA guidelines. We included studies reporting on either EVAR or open surgical repair (OSR) of late rupture (>30 days) after previous EVAR. The primary end point was perioperative (in-hospital or 30-day) mortality. A random effects meta-analysis was conducted and a meta-regression was subsequently performed to examine the impact of several variables on perioperative mortality. RESULTS: Thirty studies (743 patients, 746 ruptures) were included. The cumulative incidence of rupture after EVAR during a mean 5-year follow-up was 1.5%. The mean time from the index EVAR to rupture was 48 months (range, 16-81 months). The mean compliance with follow-up was 68% (95% confidence interval [CI], 58-77) and 32% (95% CI, 24-40) of the cases had at least one previous aneurysm-related reintervention. Type I and III endoleaks were the predominant causes of rupture (88%). Approximately one-third of the patients (37%; 95% CI, 28-47) were hemodynamically unstable. Of those undergoing an operation, 247 patients (38%) were managed endovascularly and 409 (62%) by OSR. The pooled perioperative mortality was 29.5% (30 studies; 95% CI, 23.8-35.8) and was significantly lower in the endovascular subgroup (20 studies; risk ratio, 0.62; 95% CI, 0.44-0.86). Meta-regression demonstrated that perioperative mortality seems to fall in recent years (-0.0545; P = .04), to decrease in larger series in the endovascular subgroup (-0.0375; P = .01), and to be significantly higher when total endograft explantation is required in the OSR subgroup (0.0121; P = .03). CONCLUSIONS: Late rupture after previous EVAR is a devastating event with a considerable risk for death. EVAR is associated with a significantly lower perioperative mortality and should be preferred whenever feasible. When OSR is required, total endograft explantation carries a higher mortality and, therefore, preserving functional parts of the endograft should be encouraged.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Koudounas G, Bontinis V, Giannopoulos S, et al. Rupture after previous endovascular abdominal aortic aneurysm repair: A meta-analysis and meta-regression analysis of factors influencing perioperative mortality. J Vasc Surg. 2025. PMID: 40120725. doi:10.1016/j.jvs.2025.02.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。